BAM
CYTK icon

Bellevue Asset Management’s Cytokinetics CYTK Stock Holding History

Bellevue Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19
Closed -$1.21K – 403
2025
Q4 		$1.21K Hold
19
– – ﹤0.01% 477
2025
Q3 		$1.04K Buy
+19
New +$783 ﹤0.01% 486
2024
Q4 		– Sell
-19
Closed -$1K – 494
2024
Q3 		$1K Hold
19
– – ﹤0.01% 459
2024
Q2 		$1.03K Buy
+19
New +$1.15K ﹤0.01% 462

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Bellevue Asset Management's CYTK Position: Q1 2026 in Review

Bellevue Asset Management sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 19 shares — an estimated $1.21K sold.

Bellevue Asset Management first reported a position in CYTK in Q2 2024 and held it in 4 quarters. The position peaked at $1.21K in Q4 2025. 441 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Bellevue Asset Management reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
  • Bellevue Asset Management sold 19 Cytokinetics shares in Q1 2026, an estimated $1.21K.
  • Bellevue Asset Management first reported a position in Cytokinetics in Q2 2024 and held it in 4 quarters.
  • Bellevue Asset Management's Cytokinetics position peaked at $1.21K in Q4 2025.
  • 441 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Bellevue Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.